Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Depression in Old Age
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test the feasibility and acceptability of an evidence-based treatment for depression delivered over an ipad, computer, or smartphone can help Adult Protective Services (APS) clients with their activities of daily living to evaluate whether reductions on measures of depression and apathy (a) mediate reduced Elder Neglect/Self Neglect (EN/SN) behaviors; and (b) whether secondary posited mediating mechanisms are also active in impacting depression and apathy

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: APS Treatment as Usual — APS agencies conduct in-home investigations of alleged abuse and neglect against disabled and older adults. Investigations result in short-term stop-gap measures, primarily brief case-management centering on referral linkage to community-based services and provision of resource allocation. No direct psychological services or treatments are provided by APS, however referral to other services is also standard.
  • Behavioral: Intervention-Behavioral Activation (BA) — Participants will be will be guided through 8 one-hour sessions via home telehealth by the study community health worker. Each weekly \< 60 minute BA session will include modules focusing on 1) Psychoeducation for depression and techniques for self-management, including pharmacologic and psychosocial treatment options; 2) Introduction of BA and guided problem-solving techniques to enhance self efficacy for managing depression and other chronic illnesses; 3) BA and problem-solving techniques to support medication management and adherence strategies; 4) BA to develop strategies and techniques for communicating with health providers and/or support resources to foster positive mood and self management; and 5) Developing a relapse prevention plan, which includes identifying triggers for lower functioning, support resources, and practice of BA techniques.

Primary Outcomes

  • Change in depression as assessed by the Patient Depression Questionnaire (PHQ-9) (baseline, post-treatment ( 8 weeks after baseline), and 3 months)
  • Change in apathy as assessed by the Apathy Motivations Index (AMI) (baseline, post-treatment ( 8 weeks after baseline), and 3 months)
  • Change in Elder Neglect/Self Neglect (EN/SN) as evidenced by study developed goal attainment scale (baseline, post-treatment ( 8 weeks after baseline), and 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-15
Completion: 2027-01-24
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: National Institute on Aging (NIA)
Principal Investigators:
  • Leila Wood, PhD, MSSW (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Leila Wood, PhD, MSSW
(713) 486-2700
Leila.G.Wood@uth.tmc.edu
Jason Burnett
(713) 873-4685
Jason.Burnett@uth.tmc.edu
Leila Wood, PhD, MSSW
(713) 486-2700
Leila.G.Wood@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Behavioral: APS Treatment as Usual — APS agencies conduct in-home investigations of alleged abuse and neglect against disabled and older adults. Investigations result in short-term stop-gap measures, primarily brief case-management centering on referral linkage to community-based services and provision of resource allocation. No direct psychological services or treatments are provided by APS, however referral to other services is also standard.
  • Behavioral: Intervention-Behavioral Activation (BA) — Participants will be will be guided through 8 one-hour sessions via home telehealth by the study community health worker. Each weekly \< 60 minute BA session will include modules focusing on 1) Psychoeducation for depression and techniques for self-management, including pharmacologic and psychosocial treatment options; 2) Introduction of BA and guided problem-solving techniques to enhance self efficacy for managing depression and other chronic illnesses; 3) BA and problem-solving techniques to support medication management and adherence strategies; 4) BA to develop strategies and techniques for communicating with health providers and/or support resources to foster positive mood and self management; and 5) Developing a relapse prevention plan, which includes identifying triggers for lower functioning, support resources, and practice of BA techniques.
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * APS Case in APS Region VI- Must have open case * PHQ 9 score- Must have score of nine (9) or more Exclusion Criteria: * Previous mental health diagnosis of bipolar disorder, psychotic disorders, and moderate to severe dementia * Assessment of Consent Proxy- Those who need assessment of consent proxy * Suicidal Intent (as indexed by PhQ-9 question 9)- Those scoring 2 or 3 * Current Alcohol and Drug Dependency- As evidenced by Cut down, Annoyed, Guilty, and Eye-opener (CAGE) score of 3 or more
Conditions Major Depressive Disorder, Generalized A...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this study is to identify risk factors for depression among medical students by comparing them to students who completed their first year but did not enter the medical program (students not accepted into the second year of medical school). Major Depressive Disorder (MDD) will be assessed using a validated tool: the Composite International Diagnostic Interview Short-Form (CIDI-SF). This a prospective, longitudinal, cohort study. The plan is to inform each new cohort of students at the Orléans University Hospital medical school for 10 years. It is estimated that 5,000 to 10,000 students will be able to participate in the study. A link to access the study questionnaire will be sent to students by email via the registrar's office, with one email per week for four weeks. The email will contain a link to a web page where the questionnaire can be completed. The questionnaire will be available online on computers or smartphones for six weeks: from mid-October to the end of November. The questionnaire will be completed each year for the duration of the study or until the student completes their studies. Duration of the inclusion period: 10 years Duration of participation for each participant: maximum 12 years Total duration of the study: 22 years As the cohort progresses, longitudinal analyses may be conducted to study the evolution of various disorders over time, adjusting for known confounding factors. Following the initial analyses of this study, a new interventional study will be set up to identify students at risk and offer them appropriate care.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Questionnaire — Questionnaire to be completed once a year

Primary Outcomes

  • Measure Major Depressive Disorder prevalence (Students fulfil the questionnaire on line once a year from enrollment until students complete their studies.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-22
Completion: 2047-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Régional d'Orléans
Principal Investigators:
  • Jasmina MALLET, MD-PhD (PRINCIPAL_INVESTIGATOR) - CHOrléans
Contact Information
Study Contact:
Jasmina MALLET, MD-PhD
0238229795
jasmina.mallet@chu-orleans.fr
Fanny LOUAT
0238744295
fanny.louat@chu-orleans.fr
Jasmina MALLET, MD-PhD
0238229795
jasmina.mallet@chu-orleans.fr
Centre Hospitalier Universitaire d'Orléans
Interventions
  • Other: Questionnaire — Questionnaire to be completed once a year
Study Locations (1 sites)
Centre Hospitalier Universitaire d'Orléans, Orléans, Loiret 45067 France
Eligibility Criteria
Inclusion Criteria: * Students who have been enrolled in first year of health studies at the University of Orléans * Aged 18 or over Exclusion Criteria: * Does not speak French * Person under legal guardianship * Person deprived of liberty * Person under guardianship or trusteeship
Conditions Bipolar Depression
Phase PHASE3
Enrollment 384
Locations 68 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.

Primary Outcomes

  • Children's Depression Rating Scale-Revised (CDRS-R) (Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-14
Completion: 2031-10-31
Eligibility
Age: 10 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Intra-Cellular Therapies, Inc.
Principal Investigators:
  • Intra-Cellular Therapies, Inc. Clinical Trial (STUDY_DIRECTOR) - Intra-Cellular Therapies, Inc.
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.
Study Locations (68 sites)
Harmonex Neuroscience Research, Dothan, Alabama 36303 United States
Pillar Clinical Research, LLC, Little Rock, Arkansas 72204 United States
Advanced Research Center, Inc, Anaheim, California 92805 United States
Inland Psychiatric Medical Group Inc, Redlands, California 92373 United States
UC Davis Health System, Sacramento, California 95817 United States
University of California San Diego Medical Center, San Diego, California 92103 United States
Next Level Clinical Trials, LLC, West Covina, California 91790 United States
MCB Clinical Research Centers LLC, Colorado Springs, Colorado 80910 United States
Royal Palm Clinical Research, Fort Myers, Florida 33901 United States
United Research Institute, Hialeah, Florida 33012 United States
Eligibility Criteria
Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL); 4. Subject has a lifetime history of at least one manic or hypomanic episode. 5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration; 6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline; 7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline. Exclusion Criteria: 1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes: * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. 2. Intellectual disability based on Investigator opinion and DSM-5 criteria 3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization; 4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or 3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or 4. The patient is considered to be an imminent danger to him/herself or others.
Conditions Conduct Problems, Anxiety Symptoms, Depr...
Phase NA
Enrollment 252
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is to test the effectiveness of the parent training intervention Supportive Parents - Coping Kids (SPARCK) for prevention of childhood mental health problems. The main research questions are: • Is SPARCK effective in preventing and reducing negative outcomes and promoting positive outcomes for eligible children and parents compared with regular care practice? In addition, investigators will conduct an implementation study to examine relations between implementation determinants and implementation and clinical outcomes in the SPARCK intervention condition Participants in the effectiveness trial will be randomized to receive either the SPARCK intervention or active regular care practices provided by professionals in the Norwegian frontline services. Researchers will test the effectiveness of the SPARCK intervention at post treatment and six months follow-up.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Behavioral parent or child directed intervention — Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
  • Behavioral: Supportive Parents - Coping Kids — Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.

Primary Outcomes

  • Change in symptoms of child anxiety and depression measured by Revised Child Anxiety and Depression Scale (Pre (at respondent study inclusion), post (at treatment termination or up to 25 weeks), and follow-up (6 months after post assessment))
  • Change in child problem behaviors measured by Eyberg Child Behavior Inventory (Pre (at respondent study inclusion), post (at treatment termination or up to 25 weeks), and follow-up (6 months after post assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-15
Completion: 2027-06
Eligibility
Age: 4 Years – 12 Years
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Norwegian Center for Child Behavioral Development
Collaborators: Kavli Trust
Principal Investigators:
  • Truls Tømmerås, PhD (PRINCIPAL_INVESTIGATOR) - National Center for Child Behavioral Development
Contact Information
Study Contact:
Line Ragna Aakre Karlson, MA
+4790685479
l.r.a.karlsson@nubu.no
Agathe Backer-Grøndahl, PhD
+4795211409
agathe.backer-grondahl@nubu.no
Line Tagna Aakre Karlson, MA
+4790685479
l.r.a.karlsson@nubu.no
National Center for Child Behavioral Development
Interventions
  • Behavioral: Behavioral parent or child directed intervention — Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
  • Behavioral: Supportive Parents - Coping Kids — Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
Study Locations (1 sites)
National Center for Child Behavioral Development, Oslo, Norway
Eligibility Criteria
Inclusion Criteria: * Children displaying elevated symptoms of internalizing or/and externalizing problems Exclusion Criteria: * Child is referred to or receives ongoing help in the specialized mental health services for problems in the internalizing or externalizing domains * Child is diagnosed with psychosis, mental retardation or pervasive developmental disorder * Acute suicide risk * Documented or probable ongoing physical or sexual abuse * Child or caretakers receives other systematic interventions targeting internalizing or externalizing problems while enrolled in the study (prior to 6 month follow-up)
Conditions Depression Severe
Phase NA
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Chronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull. Over time, intracalvarial cortical stimulation is intermittently activated to modulate locally and distally connected brain regions. Because of the important role played by the dorsolateral prefrontal cortex in mood regulation, the goal of this study is to apply intracalvarial prefrontal cortical stimulation (IpCS) over the dorsolateral prefrontal cortex in severely treatment-resistant depressed (TRD) patients. Per the DSM-V and Centre for Medicare and Medicaid Services (CMS) nomenclatures, TRD patients are commonly defined as those whose treatment failed to produce response or remission after 2 or more attempts of sufficient duration and treatment dose. In the investigator's study, eligible TRD subjects will have a diagnosis of major depressive disorder with a suboptimal response to an adequate dose and duration of at least two different antidepressant treatment categories. These subjects will also have had exposure and transiently (non-durably) responded to non-invasive neurostimulation. The investigator anticipates that severely Treatment Resistant Depressed (TRD) Subjects with IpCS of the dorsolateral prefrontal cortex will show a significant decrease in depression symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) at four months post-implant when compared to baseline. The investigator will enroll up to 20 subjects with severe refractory depression in an open trial, followed for up to one year. Depressive and cognitive symptoms will be rated periodically to assess the safety and efficacy of this procedure.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION — Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.

Primary Outcomes

  • Change in depression symptoms (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-28
Completion: 2027-12
Eligibility
Age: 21 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inner Cosmos Inc
Collaborators: Washington University School of Medicine, Massachusetts General Hospital
Principal Investigators:
  • Eric Lenze, MD (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Arthur Gribetz
+1 917 732 2102
arthur@innercosmos.io
Darin Dougherty, MD
617-724-6143
ddougherty@mgb.org
Massachusetts General Hospital
Karen Flavin, RN
314 747 6998
karen.flavin@wustl.edu
Washington University in St Louis School of Medicine
Interventions
  • Device: INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION — Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
Study Locations (2 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Washington University in St Louis School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: To be eligible for this study, a subject must meet all the following inclusion: 1. Subject has a diagnosis of chronic (≥ two years) or recurrent (multiple prior episodes) depression and is currently experiencing a major depressive episode as defined by DSM V criteria. 2. Subject meets a pre-treatment baseline threshold with MADRS score of \>/=20 3. Subject has not had an sustained response to two or more adequately dosed antidepressant treatments from at least two different antidepressant treatment classes in the current depressive episode according to the Antidepressant Treatment History Form (ATHF) (Gaynes, 2020). 4. The subject has completed all baseline testing to determine eligibility for the implant surgery (approximately 3 \& 2 weeks prior to expected date for implant surgery, CT \& MRI brain scans and cognitive testing). 5. Female subject is not pregnant, agrees to use adequate birth control, or is not capable of becoming pregnant (e.g. post-menopausal, no uterus, ligation of fallopian tubes, surgical removal of ovaries) 6. Subject is between the ages of 21 and 80. 7. Subject is able to complete the evaluations needed for this study including the high resolution CT and MRI brain imaging scans. 8. Subject is able to provide written informed consent and has signed the consent form for participation in this study. Exclusion Criteria: The presence of any of the following will exclude a subject from the study: 1. The IpCS would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the patient. 2. Subject is expected to require full body magnetic resonance imaging (MRI) during the clinical study. 3. Subject is judged by the investigator to be acutely suicidal (e.g., within the 30 days prior to the IpCS implant, the subject has made a suicide attempt or gesture or has made specific plans or preparation to commit suicide). 4. Subject has a history of schizophrenia, schizoaffective disorder, or other psychotic disorder, or a current major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the DSM V criteria. 5. Subject has a neurological disorder like Epilepsy, Dementia, Delirium, Amnestic disorder, and cognitive impairment. 6. Subject has a history of brain injury that resulted in cognitive impairment. 7. Subject has history of bony disorders (changes in bone density may impact the safe and effective use of the device as well a device implantation). 8. Female subjects with a positive urine pregnancy test. 9. Subject is taking a MAO inhibitor drug e.g., Isocarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), or Tranylcypromine (Panate) that may pose risk for general anesthesia. The Coordinator will Identify MAOI drug and discuss with PI. 10. Subject and/or Subject's psychiatrist DISAGREES with holding constant the subject's ongoing pharmacotherapy for 4 months following enrollment. 11. Presence of hyperostosis frontalis interna (operationally defined, frontal bone thickening of \>20mm), as determined by CT scan of the head, at the proposed site of the electrode implantation 5.3 Prohibited Therapy During Study Period No drug is prohibited, with the exception of Monoamine oxidase inhibitors (MAOIs) if they are posing a risk for general anesthesia. If a subject presents on a MAOI, this will be brought to the PI's attention for discussion with the anesthesiologist. Subjects will follow study protocol of IpCS-D. In brief, after enrolling in the IpCS-D study, all subjects will have their ongoing pharmacotherapy held constant for four months. After the 4 months, all drugs for treating mood disorders are allowed.

Temporal Interference and Depression

NCT05295888
Recruiting
Conditions Major Depressive Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Major Depressive Disorder (MDD) has a high prevalence, is the leading cause of disability, and currently available interventions are associated with side effects and high treatment resistance. There is an urgent need for the development of novel interventions for MDD with alternate mechanisms of action. Temporal Interference (TI) stimulation is a newly emerging form of transcranial alternating current stimulation (tACS) that involves the application of two high-frequency currents at slightly different kHz frequencies. Since neurons, due to their intrinsic low-pass filtering, do not respond to high frequencies (i.e. \> 100 Hz), TI relies on the 'beat' interaction leading to neuromodulation at any given location, resulting in a much smaller focus and allowing for better targeting. The subgenual cingulate cortex (SCC) appears to be critical in the pathophysiology of depression and treatment response, especially in treatment-resistant cases. Non-invasive treatments, however, are not able to accurately target SCC due to its deep location within the brain. In this trial, 30 participants meeting the diagnostic criteria for MDD will be randomized to receive 10 sessions of 130 Hz TI delivered daily for 30 minutes, or 10 sessions of sham stimulation. During the stimulation, participants will be watching emotional film clips to enhance target engagement. The investigators will collect metrics of SCC target engagement using the resting-state fMRI and EEG technologies, and determine feasibility, tolerability, safety, and therapeutic efficacy of TI stimulation in MDD. The results of this trial will inform the TI technology as a therapeutic tool for network-based psychiatric disorders, including MDD, and be vital for the design and development of a large-scale randomized-controlled trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Temporal Interference stimulation — TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
  • Device: Sham stimulation — Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.

Primary Outcomes

  • Neuroimaging - Signal variance (End of 2nd week of intervention)
  • Neuroimaging - Functional connectivity (End of 2nd week of intervention)
  • Neuroimaging - Anatomical connectivity (End of 2nd week of intervention)
  • Neuroimaging - Perfusion metrics (End of 2nd week of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-15
Completion: 2027-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Collaborators: Beth Israel Deaconess Medical Center, Northeastern University, Centre for Addiction and Mental Health, Charite University, Berlin, Germany, Toronto Metropolitan University
Principal Investigators:
  • Venkat Bhat, MD MSc (PRINCIPAL_INVESTIGATOR) - Unity Health Toronto
Contact Information
Study Contact:
Venkat Bhat, MD MSc
416-360-4000
Venkat.Bhat@unityhealth.to
Ilya Demchenko, MSc
416-360-4000
Ilya.Demchenko@unityhealth.to
Venkat Bhat, MD MSc
416-864-2755
Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto
Interventions
  • Device: Temporal Interference stimulation — TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
  • Device: Sham stimulation — Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
Study Locations (1 sites)
Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto, Toronto, Ontario M5B 1W8 Canada
Eligibility Criteria
Inclusion Criteria - Patients will be included if they: 1. provide written informed consent before initiation of any study-related procedures 2. are outpatients 3. meet the DSM-5 criteria for major depressive disorder (MDD) with a current major depressive episode (MDE) without psychotic features as confirmed at Screening by the Mini International Neuropsychiatric Interview (MINI) 4. are male or female, 18 to 65 years of age (inclusive) at screening 5. have a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥ 20 (moderate to severe depression) at screening 6. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening 7. able to adhere to the treatment schedule 8. pass the TI adult safety screening questionnaire 9. are able to understand and comply with the requirements of the study, as judged by the investigator(s) Exclusion Criteria - Patients will be excluded if they: 1. have an acute alcohol or substance use disorder, withdrawal symptoms requiring detoxification, or went through detoxification treatment (inpatient or outpatient) within 3 months before Screening, as obtained from MINI, Module I (Alcohol Use Disorder) and Module J (Substance Use Disorder, Non-Alcohol) assessed at Screening 2. have a concomitant major unstable medical illness, active hepatitis B virus (HBV), hepatitis C virus (HPC), human immunodeficiency virus (HIV), active COVID-19 infection, cardiac pacemaker or implanted medication pump, as per medical history provided by the participant 3. have active suicidal intent, confirmed by a 'Yes' response to Question B3 AND either Question B10 or B11, obtained from the MINI Suicidality, Module B (Suicidality), OR confirmed by the MADRS item #10 score ≥ 4, both assessed at Screening 4. have a current clinical diagnosis of autism, dementia, or intellectual disability 5. take medications prohibited by the protocol. Medications will be reviewed by the responsible MD 6. are pregnant or lactating 7. have any prior or current diagnosis of bipolar I or II disorder, MDD with psychotic features, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms as obtained from MINI, Module C (Manic and Hypomanic Episodes) and Module K (Psychotic Disorders and Mood Disorders with Psychotic Features) assessed at Screening 8. have any prior or current diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), confirmed by MINI and assessed by a study investigator to be primary and causing greater impairment than MDD 9. have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than MDD 10. have received TI for any previous indication due to the potential compromise of subject blinding 11. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space-occupying brain lesion, any history of seizure except those therapeutically induced by ECT or a febrile seizure of infancy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than 5 minutes, current history of poorly controlled migraines including chronic medication for migraine prevention 12. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed 13. if participating in psychotherapy, have NOT been in stable treatment for at least 3 months prior to entry into the study or anticipate change in the frequency of therapeutic sessions or therapeutic focus over the duration of the study 14. have a clinically significant laboratory abnormality, in the opinion of one of the principal investigators or study physicians 15. currently take medications that potentially limit the TI efficacy 16. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with an interview) 17. have a clinical finding that is unstable or that, in the opinion of the investigator(s), would be negatively affected by the study medication or that would affect the study medication (e.g., diabetes mellitus, hypertension, unstable angina) 18. have uncorrected hypothyroidism or hyperthyroidism. Subjects needing a thyroid hormone supplement to treat hypothyroidism will be excluded if they have NOT been on a stable dose of the medication for 30 days prior to enrolment 19. have any other condition that, in the opinion of the investigator(s), would adversely affect the subject's ability to complete the study or its measure 20. wear a hairstyle or headdress at the time of the stimulation that prevents electrode contact with the scalp or would interfere with the stimulation (e.g., thick or curly hair) 21. have any contraindications for receiving TI or undergoing MRI scans (e.g., hip circumference \>180 cm or metal in the body)
Conditions Severe Permanent Uni or Bilateral Non-pu...
Phase NA
Enrollment 7
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study aims at evaluating the effectiveness of the treatment of unilateral or bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep Brain Stimulation (DBS) of the parieto-insular right operculum 3 (OP3) in a cross-over, double study design.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: DBS — Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)

Primary Outcomes

  • Effectiveness of the treatment using Deep Brain Stimulation (DBS) of the right operculum 3 (OP3). (2.5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-04-23
Completion: 2026-10
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 7 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Grenoble
Collaborators: Commissariat A L'energie Atomique, Équipe 5 Neuroimagerie et perfusion cérébrale, Grenoble Institut des Neurosciences (GIN)
Contact Information
Study Contact:
Stéphan CHABARDES, MD, PhD
33 (0)4 76 76 93 85
SChabardes@chu-grenoble.fr
Caroline SANDRE-BALLESTER, PhD
33 (0)4 38 78 28 51
CSandreballester@chu-grenoble.fr
Stephan CHABARDES, MD, PhD
33 (0)4 76 76 93 85
SChabardes@chu-grenoble.fr
CLINATEC
Interventions
  • Device: DBS — Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
Study Locations (1 sites)
CLINATEC, Grenoble, 38000 France
Eligibility Criteria
Inclusion Criteria: 1. Between 18 and 75 years old, 2. Uni or bilateral permanent non-pulsatile tinnitus, without associated vestibular pathology, with or without hearing loss, 3. Severe tinnitus resistant to treatment failure, 4. Tinnitus intensity on the Visual Analog Scale (VAS) ≥ 7, 5. Presenting a quality of life score on the Tinnitus Handicap Inventory (THI) questionnaire\> 76 (= grade 5), 6. Social security affiliates or beneficiaries of such a scheme 7. Informed and written consent signed by the patient. Exclusion Criteria: 1. Vestibular dysfunction (balance disorder), 2. Epilepsy, 3. Intercurrent serious pathology, 4. Brain tumor, 5. Contraindication to surgery or anesthesia, 6. History of cerebral infection with herpesvirus, 7. With a contraindication to the practice of MRI, MEG, Computerized Tomography (CT) scan, 8. Under anticoagulants and antiaggregants (Anti vitamin K, low molecular weight heparin, aspirin and derivatives, clopidogrel antiplatelet agents and assimilated, new oral anticoagulants (NACO)) for which a therapeutic window can not be opened within 3 months before and after the surgery, 9. Included in another therapeutic protocol, 10. Progressive dementia or psychiatric illness, 11. Presenting a suicidal risk deemed important for less than 3 months (Montgomery and Asberg depression scale (MADRS): suicidality item (item 10) score\> 2), 12. Enforced hospitalisation, 13. Pregnant, parturient or breastfeeding, lack of contraception in patients with the capacity to procreate, 14. Subject to a legal protection measure, 15. Deprived of liberty by judicial or administrative decision, 16. Isolated patient without any contact in case of emergency.
Conditions Major Depressive Episode
Phase PHASE3
Enrollment 60
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Unipolar major depressive disorder is the leading cause of disability worldwide. The most commonly used treatments for major depressive episodes (MDE) are antidepressant medications. However, they have limited efficacy and their onset of action is long, ranging between 2 to 6 weeks. During this period, hospitalization can become necessary, especially for severe MDE. It is crucial to improve the early effectiveness of treatments for these patients in order to alleviate their suffering, limit complications (suicidal risk), and reduce hospitalization durations (approximately 1000 euros per day). The efficacy of intravenous ketamine has been demonstrated in pharmaco-resistant depression but remains to be proven in non-pharmaco-resistant severe MDE. Additionally, PET imaging using \[11C\]UCB-J, which allows the in vivo study of synaptic density in the human brain, has shown significant decreases in synaptic density in unipolar patients with severe MDE. Furthermore, a single ketamine infusion was found to enhance synaptogenesis

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Ketamine — Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
  • Drug: Placebo — Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)

Primary Outcomes

  • the early efficacy on depressive symptomatology (at day 0 and day 7)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-10-20
Completion: 2026-04
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Romain COLLE (PRINCIPAL_INVESTIGATOR) - Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre
Contact Information
Study Contact:
Romain COLLE
+33145212524
romain.colle@aphp.fr
Emmanuelle CORRUBLE
+33145212524
emmanuelle.corruble@aphp.fr
Romain COLLE, MD - PHD
+33145212524
romain.colle@aphp.fr
Psychiatry unit
Interventions
  • Drug: Ketamine — Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
  • Drug: Placebo — Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study Locations (4 sites)
Psychiatry unit, Le Kremlin-Bicêtre, France 94270 France
EPS Barthélémy Durand, Étampes, 91152 France
Bicetre Hospital - CRC, Le Kremlin-Bicêtre, 94250 France
CEA/SHFJ, Orsay, 94401 France
Eligibility Criteria
Inclusion Criteria: * Current MDE in the context of unipolar major depressive disorder (DSM-5 criteria), hospitalized (open care) for this episode, with a minimum HDRS score of 24 and in the context of an indication for the introduction of venlafaxine treatment. * Patient aged between 18 and 65. * Signed free and informed consent * Membership of a social security scheme * For women of childbearing age, effective contraception throughout study participation.\* (\*Combined hormonal contraception (containing estrogen and progestin) associated with ovulation inhibition: (oral, intravaginal, transdermal), Progestin-only hormonal contraception associated with ovulation inhibition: (oral, injectable, implantable), Intrauterine device (IUD), Hormonal intrauterine system (IUS), Bilateral tubal occlusion, Vasectomized partner, Sexual abstinence.) Exclusion Criteria: * Criteria relating to associated pathologies entailing particular risks: pharmaco-resistant CDE (failure of at least two properly conducted treatments with two different antidepressant treatment classes), CDE with psychotic features, psychotic disorder, bipolar disorder, current (\<1 month) substance use disorder (excluding tobacco). * Liver impairment (AST and/or ALT \> 3 ULN, PAL and/or GGT and/or bilirubin \> 2 ULN). * Severe renal insufficiency (GFR \<30ml/min with Cockcroft's formula). * Bradycardia less than 55 beats per minute. * Contraindication to ketamine : Hypersensitivity to active substance or excipients, comatose state, central nervous system (CNS) depression, Parkinson's disease, Lewy body dementia, progressive supranuclear palsy, known prolongation of the QTc interval (\>450ms for men and \>470ms for women) or congenital long QT syndrome, recent acute myocardial infarction, uncompensated heart failure, history of ventricular arrhythmias or torsades de pointes, uncorrected hypokalemia (K+ \< 3. 5 mmol/l), epilepsy, uncontrolled hypertension, porphyria, history of stroke (CVA), intracranial hypertension. * Contraindication to venlafaxine (hypersensitivity to venlafaxine or excipients, are hereditary conditions of fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency, unstable hypertension, no indication for venlafaxine treatment in clinician's opinion due to ineffectiveness or tolerability of previous venlafaxine treatment). * Current or previous treatment with venlafaxine or ketamine in the month prior to study inclusion. * Need to maintain another antidepressant, MAOI, Millepertuis or benzodiazepines (cyamemazine is permitted). Or potential drug interactions in case of recent cessation of these treatments (based on the Summary of Product Characteristics (SmPC) of the respective medication(s) and their half-life). * Any other unspecified reason (clinically significant illness or anomaly) which, in the opinion of the investigator or the sponsor, could compromise the safety of the participant. * Pregnant or breast-feeding patients (women of childbearing potential must have a negative urine or blood test for human chorionic gonadotropin prior to trial entry). Planned pregnancy within three months of enrolment * Adult under guardianship, curatorship or safeguard of justice * Participating in other interventional research involving the human body or within the exclusion period following previous research involving the human body, if applicable. * Social insurance Additional criteria for inclusion in the ancillary study : \- Contraindications to \[11C\]UCB-J PET-MRI 1. Absolute contraindications: Pacemaker or neurosensorial stimulator or implantable defibrillator; clip on a brain aneurysm or vascular malformation; intraocular or intracerebral ferromagnetic foreign body; prostheses or objects or mobile ferromagnetic metal fragments; cochlear implants; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; automated injection device such as insulin pump, glucose sensor; permanent eyelid or lip makeup; non-removable piercing; claustrophobia. 2. Relative contraindications: Dental prostheses and orthodontic material; certain intrauterine devices; certain tattoos; certain transdermal patch implants; certain metal implants far from the examined area. (The investigator physician and/or radiology operator will always conduct a precise questionnaire before the examination to ensure perfect safety and absence of MRI danger)
Conditions Multiple Sclerosis, Multiple Sclerosis (...
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction. For this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Prevalence of sexual dysfunction in female patients with multiple sclerosis (At enrollment (Baseline, cross-sectional assessment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-16
Completion: 2025-11
Eligibility
Age: 25 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ege University
Principal Investigators:
  • Yesim Akkoc, M.D., Prof (STUDY_DIRECTOR) - Ege University Faculty of Medicine, Department of Physical Medicine and Rehabilitation
Contact Information
Study Contact:
Merve Dokumaci, Resident doctor
+905435088428
dokumacimerve@gmail.com
Interventions
N/A
Study Locations (1 sites)
Ege University Faculty of Medicine, Department of Neurology, Izmir, Bornova 35100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Female patients aged 25-50 years * Literate and able to comprehend written and spoken instructions * Diagnosed with relapsing-remitting form of multiple sclerosis * Having a continuous/regular sexual partner * Expanded Disability Status Scale (EDSS) score ≤ 5 * At least 3 months since the last relapse * Sexually active within the past 3 months * Spasticity level \< grade 2 according to the Modified Ashworth Scale Exclusion Criteria: * Pregnancy * Illiteracy or inability to understand spoken or written instructions * Absence of a continuous/regular sexual partner * Expanded Disability Status Scale (EDSS) score \> 5 * Not sexually active within the past 3 months * Spasticity level ≥ grade 2 according to the Modified Ashworth Scale
Conditions COPD (Chronic Obstructive Pulmonary Dise...
Phase PHASE2
Enrollment 108
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are: * Can psilocybin therapy safely reduce depressive symptoms compared to low-dose control? * Will the therapeutic effects be rapid and sustained over a 6-month period? Researchers will compare patients receiving two escalating doses of psilocybin (15mg followed by 25mg) against those receiving two low doses (1mg) to see if the higher doses lead to greater improvements in depression, anxiety, demoralization, and quality of life. Participants will: * Attend three preparation sessions with psychotherapists (1-2 hours each) * Undergo two supervised psilocybin dosing sessions (6-8 hours each) * Complete five integration therapy sessions following the dosing sessions * Participate in follow-up assessments at 6 weeks, 3 months, and 6 months * Have access to a digital care platform and peer support groups during the 6-month follow-up period * Optional: Control group participants may receive one high-dose psilocybin session (25mg) after the initial study period

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Psilocybin therapy — Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists

Primary Outcomes

  • Depressive symptoms (MADRS) (Baseline (Day -14) to Primary Endpoint (Day 56))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-01
Completion: 2028-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Center Groningen
Collaborators: HumanKindLabs, University of Copenhagen, CTC Clinical Trial Consultants AB, OPEN Foundation, IESE Business School, Uppsala University, The Champalimaud Centre, Lisbon, Portugal, Stockholm University, University of Groningen, The Netherlands, National Institute of Mental Health, Czech Republic, European Association for Palliative Care, Madopa, Bispebjerg Hospital, European Association of Neurological Associations (EFNA), 29k International AB, Lung Alliance Netherlands, European Psychiatric Association, Norrsken Mind
Contact Information
Study Contact:
Robert A Schoevers, Professor
050 361 2008
r.a.schoevers@umcg.nl
Tomas Palenicek
tomas.palenicek@nudz.cz
National Institute of Mental Health
Tomas Palenicek
National Institute of Mental Health
Interventions
  • Drug: Psilocybin therapy — Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Study Locations (4 sites)
National Institute of Mental Health, Prague, Czechia
Bispebjerg Hospital, Copenhagen, Denmark
University Medical Center Groningen, Groningen, Provincie Groningen Netherlands
Champalimaud Foundation, Lisbon, Portugal
Eligibility Criteria
Inclusion Criteria: 1. Patient has to be diagnosed with one of the following four conditions, defined as: COPD i) Diagnosis by medical specialist ii) Postbronchodilator FEV1/FVC \< 0,7 and FEV1 \<80% pred iii) ≥ 40 years old iv) ≥ 10 years smoking ALS i) ALS according to Goldcoast criteria (Shefner et al, Clin Neurophysiol, 2020) ii) ALS-FRS-R subscores of minimum 1 in item 2, 3 and 8, subscore of minimum 2 in item 1, 4 and 10 and a subscore of minimum 3 in item 11 and 12 MS i) Fulfilled diagnostic revised McDonald criteria for MS from 2017 (Thompson et al., 2018) ii) EDSS ≥ 1,0 APD i) Advanced to Late-Stage Parkinson's Disease - patients with a diagnosis of Parkinson's Disease per the MDS clinical diagnosis criteria with evidence of motor and non-motor fluctuations ii) Diseases in the spectrum of Progressive supranuclear palsy (PSP), fulfilling possible and probable criteria, according to the MDS diagnostic criteria iii) Clinically Established and Clinically Probable Multiple System Atrophy (MSA) according to the MDS diagnostic criteria 2. Patient meets ICD-10 criteria for major depressive disorder documented through the com-pletion of the mood section of the Mini International Neuropsychiatric Interview by a screen-ing psychologist or physician. 3. Patient has a MADRS score of \> 19. 4. Patient should have a life expectancy of at least 6 months (assessed by study physician). 5. Patient is at least 18 years of age. 6. Patient has an identified caregiver/support person. See specific conditions for Czechia in Appendix 5. 7. Patient is able to read and understand the informed consent and all scales used in a local language. For those with ALS, MS, or APD, competency is ensured via neurologist assessment, cognitive screening, caregiver support during screening and interactive approaches where the screening clinician ask the patient to explain their understanding of consent elements, re-explaining potentially misunderstood information. 8. Patient is able to and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations. 9. Patient is able to ingest capsules. Exclusion Criteria: 1. Patient has used a psychedelic substance in the past 6 months (e.g., psilocybin, LSD, 5-MeO-DMT, DMT, ayahuasca or mescaline). 2. Patient is in active treatments for other psychiatric disorders, judged by the screening clinician to be a more significant clinical problem than depression / distress. 3. Patient meets ICD-10 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features (except substance/medication-induced or due to another medical condition) or bipolar I/II disorder. 4. Patients with any lifetime diagnosis of schizophrenia spectrum or other psychotic disorders. 5. Patient has a first-degree relative with schizophrenia spectrum, bipolar I disorder or other psychotic disorders (expect substance/medication-induced or due to another medical condition). 6. Patients with a pre-existing psychiatric condition judged to be incompatible with safe exposure to psilocybin therapy. 7. Significant suicide risk as defined by (1) suicidal ideation with intent to act (defined as ≥ 5 on MADRS item 10), (2) suicidal attempts within the past year, or (3) clinical assessment of significant suicidal risk during patient interview. 8. Patient meets ICD-10 criteria for active/current alcohol or drug use disorder. 9. Patient has ongoing treatment with antipsychotic drugs. Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug at the time of baseline (see Appendix 1a for Prohibited medications). 10. Patient is unwilling or unable to pause formal psychotherapy (days 0-42). 11. Patient has neurological conditions (e.g., intracranial tumour, epilepsy, brain injuries, or other neurological disorders) expected by the PIs to conflict with the treatment / study protocol. 12. Disease-specific exclusion criteria: COPD: Unresolved exacerbation or pulmonary infection within last 4 weeks. ALS: Significant cognitive deficits (MoCa, see below). MS: Significant cognitive deficits (MoCa, see below), epilepsy or radiologically isolated syndrome. APD: Dementia (MoCa, see below), or Schwab and England ADL scale with scores \> 80% in the best functional state. 13. Cardiovascular conditions: recent stroke (\< 1 year from signing of ICF), recent myocardial infarction (\< 1 year from signing of ICF), uncontrolled hypertension (blood pressure \> 140/90 mmHg), clinically significant arrhythmia within 1 year of signing the ICF, or QTc prolongation exceeding 450ms (males) / 470ms (females). 14. Patient has moderate to severe hepatic impairment (Child-Pugh score ≥ 7). 15. Patient has insulin-dependent diabetes or who are taking oral hypoglycaemic agents and have a current risk of hypoglycaemia that would require medical intervention. 16. Patient has any physical or psychological symptoms, medications, blood test results or clinically significant findings at Screening or Baseline (based on the clinical judgement of clinical/medical study personnel) that would make a patient unsuitable for the study. 17. Patient has an allergy or intolerance to any of the materials contained in either drug product. 18. Cognitive and Neuropsychological assessment: Patients will be excluded if they score below mean minus 1.5 Standard Deviation according to normative age and scholarity adjusted data on the Montreal Cognitive Assessment (MoCA) assessment. 19. Recent (2 weeks) change or planned change in antidepressant medication during the intervention. 20. Women who are pregnant, intend to become pregnant during the study or who are currently nursing, or are unwilling to use Highly Effective Contraceptive Methods
Conditions Depressive Disorder
Phase Not Applicable
Enrollment 600
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: electroconvulsive therapy — electroconvulsive therapy

Primary Outcomes

  • Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at posttreatment; MADRS range 0 - 60, with higher scores indicating more severe depression) (up to 8 weeks)
  • Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at posttreatment; MMS-E range 0-30 with lower scores indicating more severe cognitive impairment (up to 8 weeks)
  • Change of Beck depression inventory (BDI) score from pretreatment at posttreatment; BDI range 0-63, with higher scores indicating more severe depression (up to 8 weeks)
  • Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at posttreatment with higher scores indicating more severe impairment (up to 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-03-13
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Haukeland University Hospital
Collaborators: Helse Stavanger HF
Contact Information
Study Contact:
Ute Kessler, PhD
ute.kessler@helse-bergen.no
Ute Kessler, PhD
ute.kessler@helse-bergen.no
Haukeland University Hospital
Ute Kessler, PhD
Haukeland University Hospital
Interventions
  • Other: electroconvulsive therapy — electroconvulsive therapy
Study Locations (2 sites)
Haukeland University Hospital, Bergen, 5021 Norway
Stavanger University Hospital, Stavanger, Norway
Eligibility Criteria
Inclusion Criteria: * Patients treated with ECT for major depression (F31.3-5, F32, F33) at Haukeland University Hospital or Stavanger University Hospital after 2013, * written consent to enrolment into the Regional Register for neurostimulation. Exclusion Criteria: * ECT performed on other indications than major depression. * No consent to the register.

Neurobiology of Suicide

NCT02543983
Recruiting
Conditions Healthy Volunteers, Depression
Phase PHASE2
Enrollment 325
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies. They hope to better understand suicide, so they can help suicidal people. Objective: To understand what happens in the brain when someone has thought about or attempted suicide. Eligibility: Group 1: Adults ages 18 70 who have thought about or attempted suicide recently Group 2: Adults ages 18 70 who have thought about or attempted suicide in the past Group 3: Adults ages 18 70 who have depression or anxiety, but have never thought about suicide Group 4: Healthy volunteers the same ages. Design: Participants will be screened in another protocol. Adults who have recently thought about or attempted suicide must be referred by a doctor. They may do up to 3 phases of this study. Groups 2, 3 and 4 will do only Phase 1 and will not get ketamine. Phase 1: 1 week in hospital. Participants will have: Physical exam. Questions about thoughts and feelings. Thinking and memory tests and simple tasks. Blood and urine tests. Two MRI scans. Participants will lie on a table that slides into a metal cylinder that takes pictures. They will have a coil over their head and earplugs and do a computer task. Sleep test. Disks and bands will be placed on the body to monitor it during sleep. Magnetic detectors on their head while they perform tasks. A wrist monitor for activity and sleep. Lumbar puncture (optional). A needle will collect fluid from the back. Shock experiments (optional). Participants will observe pictures and sounds and feel a small shock on the hand. Phase 2: 4 days in hospital. A thin plastic tube will be placed in each arm, one for blood draws, the other to get the drug ketamine once. Participants will repeat most of the Phase 1 tests. Phase 3: up to 4 more ketamine doses over 2 weeks. Participants will have follow-up calls or visits at 6 months and then maybe yearly for 5 years.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Magnetic Resonance Imaging scanner, 3T — Non-significant risk device used for brain imaging.
  • Device: NeurOptics PLRTM-3000 Pupillometer — The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
  • Device: Experimental Anxiety Devices — Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
  • Device: Magnetic Resonance Imaging scanner, 7T — Non-significant risk device used for brain imaging.
  • Drug: Ketamine Hydrochloride — A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.

Primary Outcomes

  • Study as Whole: Psychiatric, psychological, neuroimaging, sleep and biological differences between participants in Groups 1, 2, 3, 4, and 5 (multiple time-points)
  • Phase II: Scale for Suicide Ideation (multiple time-points)
  • Phase II: Montgomery-Asberg Depression Rating Scale (multiple time-points)
  • Phase II: Hamilton Psychiatric Rating Scale for Anxiety (multiple time-points)
  • Phase II: Clinical Global Impression Scale (multiple time-points)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2015-12-01
Completion: 2030-07-21
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: true
Enrollment: 325 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Carlos A Zarate, M.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Laura R Waldman, L.C.S.W.
(301) 768-2833
laura.waldman@nih.gov
Carlos Zarate, M.D.
877-646-3644
moodresearch@mail.nih.gov
National Institutes of Health Clinical Center
Interventions
  • Device: Magnetic Resonance Imaging scanner, 3T — Non-significant risk device used for brain imaging.
  • Device: NeurOptics PLRTM-3000 Pupillometer — The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
  • Device: Experimental Anxiety Devices — Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
  • Device: Magnetic Resonance Imaging scanner, 7T — Non-significant risk device used for brain imaging.
  • Drug: Ketamine Hydrochloride — A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Phase I: Groups 1-3 and 5 (Patients) 1. 18 to 70 years of age. 2. A level of understanding sufficient to agree to all required tests and examinations, sign an informed consent document and verify understanding by a score \>= 90% on the Baseline consent quiz 3. Individuals who are able to get pregnant must be willing to remain sexually abstinent or use at least one form of effective birth control during participation in Phase I. 4. Additional Criteria for Group 1 (Active Crisis): Agree to be hospitalized Phase I: Group 4 (Healthy Volunteers) 1. 18 to 70 years of age. 2. A level of understanding sufficient to agree to all required tests and examinations, sign an informed consent document. 3. Individuals who are able to get pregnant must be willing to remain sexually abstinent or use at least one form of effective birth control during participation in Phase I. Phase II: Group 1 (Active Crisis) and Group 5 (Suicide Ideators) 1. Patients must have completed Study Phase I as a participant in Group 1 or 5 2. Participants must verify understanding of the protocol by a score \>= 80% on the Ketamine Response consent quiz. 3. Patients in Group 1 or 5 must report at least minimal suicidal ideation, depressive or anxiety symptoms to be eligible for this phase. * MADRS score of over 10 (10 used as an outcome measure for remission)126 * OR HAMA score of over 7 (7 used as an outcome measure for remission)127 * OR SSI score of 2 or more (indicates any residual suicidal thoughts) 4. Individuals who are able to get pregnant must be willing to remain sexually abstinent or use at least one form of effective birth control during participation in Phase II. Phase III: Group 1 (Active Crisis) and Group 5 (Suicide Ideators) 1. Participants must have met all inclusion criteria for and completed Study Phase II as a participant in Group 1 (active crisis) or Group 5 (Suicide Ideators). 2. Individuals who are able to get pregnant must be willing to remain sexually abstinent or use at least one form of effective birth control during participation in Phase III. EXCLUSION CRITERIA: Phase I: Groups 1-3 and 5 (Patients) 1. Current psychotic features or cognitive impairment that would preclude understanding of the consenting process or tests/examinations. 2. Current drug or alcohol dependence 3. Currently intoxicated or under the acute effects of an illicit substance will not be consented into the study. 4. Pregnant or nursing individuals or those who plan to become pregnant. 5. Serious, unstable medical conditions/problems including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including blood pressure, ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. 6. Clinically significant abnormal laboratory tests. 7. Positive HIV test 8. Participants who, in the investigator s judgment, pose a current homicidal risk or pose suicide risk that cannot be managed in a secure, voluntary inpatient setting. 9. Non-English speakers 10. Additional Criteria for Group 1 (Active Crisis): For participants who still experience the effects of their suicide attempt, i.e. someone who overdosed is significantly drowsy or confused, the consenting process will occur after the patient has improved from the effects. If there is a concern around a participant's capacity to consent, the Human Subjects Protections Unit (HSPU) team member who is monitoring the informed consent process will complete a capacity assessment. Participants who are determined not to have capacity to consent to research will not be included in the study. Phase I: Group 4 (Healthy Volunteers) 1. Current or past Axis I diagnosis 2. Presence of medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications. 3. Current or past alcohol or substance abuse or dependence diagnosis (except for nicotine or caffeine) (or "substance abuse disorder" per DSM-V). 4. Presence of psychiatric disorders or a history of suicide attempt or death in first-degree relatives. 5. Pregnant or nursing individuals or those who plan to become pregnant. 6. No lifetime suicide attempts or ideations 7. Non-English speakers 8. Positive HIV test Exclusions for Imaging: 1. Participants with metal objects implanted in the body, such as aneurysm clips, neural stimulators, implanted cardiac pacemakers, or auto-defibrillator, cochlear implant, or ocular foreign body which would make having an MRI scan unsafe 2. Participants who are uncomfortable in small closed spaces (have claustrophobia) and would feel uncomfortable in the MRI machine 3. Participants with a brain abnormality on an initial MRI scan 4. Subjects with hearing loss that has been clinically evaluated and diagnosed and may be worsened through participation in imaging procedures Phase II: Group 1 (Active Crisis) and Group 5 (Suicide Ideators) 1. Treatment with a reversible MAOI within 2 weeks prior to study Phase II. 2. Treatment with any other concomitant medication not allowed within 5 1/2 half-lives prior to study Phase II. 3. Subjects with one or more seizures without a clear and resolved etiology 4. Participants with a positive urine for an illicit substance no more than 24 hours prior to the ketamine infusion. 5. Presence of current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-V 6. Pregnant or nursing individuals or those who plan to become pregnant. 7. A medical finding or condition that in the clinical judgement of the investigator increases the risk of adverse effects from the ketamine administration (for example: findings suggesting difficulties with kidney or cardiac function that may be contraindications for an experimental intervention). Phase III: Repeated Administration (Group 1) and Group 5 (Suicide Ideators) 1. Intolerable or serious adverse reaction to ketamine during Phase II 2. Treatment with a reversible MAOI within 2 weeks prior to study Phase III. 3. Treatment with any other concomitant medication not allowed within 5 1/2 half-lives prior to study Phase III. 4. Subjects with one or more seizures without a clear and resolved etiology 5. Participants with a positive urine for an illicit substance no more than 24 hours prior to each ketamine infusion. 6. Presence of current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-V 7. Pregnant or nursing individuals or those who plan to become pregnant. Exclusions for Imaging: 1. Participants with metal objects implanted in the body, such as aneurysm clips, neural stimulators, implanted cardiac pacemakers, or auto-defibrillator, cochlear implant, or ocular foreign body which would make having an MRI scan unsafe 2. Participants who are uncomfortable in small closed spaces (have claustrophobia) and would feel uncomfortable in the MRI machine 3. Participants with a brain abnormality on an initial MRI scan 4. Subjects with hearing loss that has been clinically evaluated and diagnosed and may be worsened through participation in imaging procedures